SCHEMBL1706527

SCHEMBL1706527

[CH2]Cc1cc(C)cc(C)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
TSHR P16473 2/20 0.40
PGK1 P00558 1/20 0.37
PGK2 P07205 1/20 0.37
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
IDH1 O75874 1/20 0.34
ACHE P22303 1/20 0.33
MAOA P21397 1/20 0.32
CISD1 Q9NZ45 1/20 0.32
TPMT P51580 1/20 0.32
TACR1 P25103 2/20 0.31
HTT P42858 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
TAAR1 Q96RJ0 1/20 0.31
CNR1 P21554 1/20 0.31
PRSS1 P07477 1/20 0.31
PRSS2 P07478 1/20 0.31
C1S P09871 1/20 0.31
PRSS3 P35030 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6741468 0.87 ALDH1A1 (0.57) ALDH1A1TSHRPGK1PGK2CYP11B1
SCHEMBL10823008 0.84 PGK1 (0.37) PGK1PGK2
SCHEMBL16953447 0.82 ACHE (0.36) PGK1PGK2IDH1ACHE
SCHEMBL16954435 0.82 TACR1 (0.40) ALDH1A1PGK1PGK2TACR1
SCHEMBL4825346 0.82 RAPGEF4 (0.33) TSHRPGK1PGK2CNR1
SCHEMBL6130297 0.77 ALDH1A1 (0.36) ALDH1A1TSHRPGK1PGK2CYP11B1
SCHEMBL6742065 0.77 CYP2A6 (0.38) ALDH1A1IDH1
SCHEMBL9306852 0.75 ALDH1A1 (0.61) ALDH1A1TSHRACHETPMTPRSS1
SCHEMBL1145705 0.75 ALDH1A1 (0.40) ALDH1A1TSHRPGK1PGK2CYP11B1
SCHEMBL3690305 0.73 ALDH1A1 (0.44) ALDH1A1TSHRPGK1PGK2CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112867706-A MASP-2 inhibitors and methods of use 奥默罗斯公司 2021-05-28 CN claimed
EP-3802489-A2 MASP-2 INHIBITORS AND METHODS OF USE Omeros Corporation (US) 2021-04-14 EP claimed
WO-2017199103-A1 BENZAMIDE COMPOUNDS AS ROR GAMMA MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2017-11-23 WO claimed
CN-1932663-B Electrophotographic image forming apparatus and process cartridge RICOH KK 2010-11-17 CN claimed
US-7304086-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2007-12-04 US claimed
US-6620823-B2 Antiinflammatory agents; rheumatic disorders BRISTOL-MYERS SQUIBB PHARME COMPANY 2003-09-16 US claimed
CN-117964684-A MASP-2 inhibitors and methods of use 奥默罗斯公司 2024-05-03 CN disclosed
CN-117964683-A MASP-2 inhibitors and methods of use 奥默罗斯公司 2024-05-03 CN disclosed
WO-2023101004-A1 OLEFIN RESIN, METHOD FOR MANUFACTURING SAME, AND APPLICATION FOR SAME 三井化学株式会社 2023-06-08 WO disclosed
US-20230145071-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION 2023-05-11 US disclosed
US-11584714-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2023-02-21 US disclosed
CN-112867706-A MASP-2 inhibitors and methods of use 奥默罗斯公司 2021-05-28 CN disclosed
EP-3802489-A2 MASP-2 INHIBITORS AND METHODS OF USE Omeros Corporation (US) 2021-04-14 EP disclosed
EP-0284863-A2 (Meth)acrylic-acid-ester-modified organic polysiloxanes, process for their preparation and their use as abhesive coatings Th. Goldschmidt AG (DE) 1988-10-05 EP disclosed
EP-0254799-A1 (Meth)acrylic ester modified organopolysiloxanes, process for making them and their use as adhesive coating compositions Th. Goldschmidt AG (DE) 1988-02-03 EP disclosed
EP-0125020-A1 Anti-treeing additives DOW CORNING CORPORATION (US) 1984-11-14 EP disclosed
EP-0109797-A2 Polymeric compositions resistant to electrical and water treeing DOW CORNING CORPORATION (US) 1984-05-30 EP disclosed
US-4394505-A ANTITUMOR AGENTS SHIONOGI & CO., LTD. (JP) 1983-07-19 US disclosed
EP-0064033-A1 5-Fluorouracil derivatives SHIONOGI & CO., LTD. (JP) 1982-11-03 EP disclosed
US-3997579-A CATALYSTS FOR THE HYDROCYANATION OF ETHYLENE E. I. DU PONT DE NEMOURS AND COMPANY (US) 1976-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584714-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 ALDH1A1 4701/4885TSHR 3558/4885PGK1 3560/4885
US-20230145071-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 ALDH1A1 4701/4885TSHR 3558/4885PGK1 3560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.